Stock Groups

Drugmaker Sanofi raises 2021 profit guidance again after Q3 beat -Breaking

by Mike Robinson

[ad_1]

© Reuters.

(Reuters) – French drugmaker Sanofi (NASDAQ:) It has raised its profit guidance to 2021 after its phenomenal eczema drug Dupixent, and its flu vaccines, helped it surpass market expectations in the third quarter.

Following a disappointing COVID-19 jab-race, the group reported that its sales increased by 10.1% to 10.4 million euros ($12.1 trillion) in September. Earnings per share was 2.18 euros. This compares to a forecast of 1.99 euros from an analyst provided by the company.

Sanofi expects that earnings per share will rise by approximately 14% in constant currencies, which is an increase from the July estimate of 12%.

($1 = 0.8618 euros)

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]